

Management Certification

The undersigned, on behalf of Regen BioPharma, Inc ("the Company"), certifies that the information provided herein is accurate and complete to the best of the Company's knowledge.

1. The Company is current in its disclosure obligations pursuant to the following reporting standard:

SEC Reporting Obligations

- The Company has a reporting obligation under Section 13 or 15(d) of the Exchange Act
- The Company has a reporting obligation under Regulation A (Tier 2)
- The Company has a reporting obligation under Regulation Crowdfunding (CF)
- Other (please describe)

Other Reporting Obligations

- The Company is a U.S. bank, bank holding company, or similar financial institution exempt from SEC registration, has a reporting obligation to a U.S. Bank Regulator and follows OTC Markets' Bank Reporting requirements.
 - The Company is exempt from SEC registration and is reporting under the Alternative Reporting Standard
2. Indicate below whether the Company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: No:
 3. Indicate below whether the Company is subject to Bankruptcy or reorganization proceedings.

Yes: No:
 4. The Company has a Verified Company Profile on OTCMarkets.com.
 5. The Company is duly organized and in good standing under the laws of the state or jurisdiction in which the Company is organized or does business.
 6. The Company understands and acknowledges its obligations to report company-related actions pursuant to Exchange Act Rule 10b-17 and FINRA Rule 6490.
 7. The Company understands and acknowledges its obligations to publicly disclose material information in a timely manner in accordance with applicable U.S. federal securities laws, including but not limited to Section 10(b) of the Exchange Act and Rule 10b-5 thereunder.
 8. The Company's transfer agent and its address are listed below. If the Company acts as its own transfer agent, indicate that by listing the Company and its information in the fields provided.¹

Transfer Agent: Nevada Agency and Transfer Company
Address: 50 W Liberty St #880 Reno, NV 89501

¹ OTCQX, OTCQB, and OTCID companies are required to retain a transfer agent that participates in the Transfer Agent Verified Shares Program. OTCID companies that act as their own transfer agent may submit data directly to OTC Markets.
OTC Markets Group Inc.
Management Certification (Version 1.3 April 2025)

9. The Company's most recent Annual Report was prepared by:

Below is a list all law firm(s) and attorney(s) (including internal counsel) that acted as the Company's primary legal counsel in preparing its most recent annual report or, if no attorney assisted in preparing the disclosure, the person(s) who prepared the disclosure and their relationship to the Company.

BCRG Certified Public Accountants and Consultants

10. The Company's Officers, Directors and 5% Beneficial Owners are listed below:

The table below provides information regarding all officers and directors of the Company, or any person that performs a similar function, regardless of the number of shares they own. To the best of the Company's knowledge, it includes all individuals or entities beneficially owning 5% or more of any class of the issuer's equity securities. To identify holders of 5% or more, companies may obtain a recent copy of their shareholder list that includes Non-Objecting Beneficial Owners or "NOBOs." SEC Reporting companies may also research their beneficial ownership and insider transaction filings such as on Schedules 13G or 13D or on Forms 3, 4, and 5.

As of (latest practicable date): 11/10/2025

Individual Name (First, Last) or Entity Name (Include names of control person(s) if a corporate entity)	Position/Company Affiliation (ex: CEO, ≥ 5% beneficial owner)	City and State (Include Country if outside U.S.)	Number of Shares Owned (List common, preferred, warrants and options separately)	Class of Shares Owned	Percentage of Class of Shares Owned (undiluted)
David R Koos	Chairman & CEO	La Mesa, CA	27,436,799	Common	27%
David R Koos	Chairman & CEO	La Mesa, CA	413,288	Series A	4%
David R Koos	Chairman & CEO	La Mesa, CA	7,667	Series M	26%
David R Koos	Chairman & CEO	La Mesa, CA	334	Series AA	100%
David R Koos	Chairman & CEO	La Mesa, CA	15,007	NC	100%

Any additional material details, including conversion terms of any class of the issuer's equity securities, are below:

11. The Company has Convertible Debt as detailed below:

The following is a complete list of the Company's Convertible Debt which includes all promissory notes, convertible notes, convertible debentures, or any other debt instruments convertible into a class of the issuer's equity securities. The table includes all issued or outstanding convertible debt at any time during the last complete fiscal year and any interim period between the last fiscal year end and the date of this Certification.

Check this box to confirm the Company had no Convertible Debt issued or outstanding at any point during this period.

Date of Note Issuance	Principal Amount at Issuance (\$)	Outstanding Balance (\$) (Include accrued interest)	Maturity Date	Conversion Terms (e.g., pricing mechanism for determining conversion of instrument to shares)	# Shares Converted to Date	# of Potential Shares to be Issued Upon Conversion ²	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g., Loan, Services, etc.)
5/5/2017	200,000	367,562	5/2/2020	A 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender.	0	57,656,784	Clay Morel	Loan
4/6/2016	50,000	87,699	4/6/2019	\$150 per share	0	585	Mikules Family Trust Kelly Mikules Trustee	Loan
3/8/2016	100,000	176,297	3/8/2019	\$150 per share	0	1,175	Reiss Family Survivors Trust Claire Reiss Trustee	Loan
12/20/2017	100,000	177,726	12/20/2020	A 75% discount to the closing price of the common stock of the company on the trading day immediately prior to the date a conversion	0	28,210,476	Joel S Wright	Loan

² The total number of shares that can be issued upon full conversion of the Outstanding Balance. The number should not factor any "blockers" or limitations on the percentage of outstanding shares that can be owned by the Noteholder at a particular time. For purposes of this calculation, please use the current market pricing (e.g. most recent closing price, bid, etc.) of the security if conversion is based on a variable market rate.

				notice is given by the Lender.				
10/3/2017	50,000	89,823	10/3/2020	a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender.	0	14,257,619	Roger Formisano	Loan
9/4/2024	250,000	316,550	9/4/2025	90% of the lowest share trading price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender.	12,500,000	92,558,479	Coventry Enterprises LLC Jack Bodenstein Managing Member	Loan
3/10/2023	48,500	36,774	3/10/2024	The note may be converted into the common shares of Regen BioPharma, Inc at a price per share ("conversion price") equivalent to the lower of (a) a 50% discount to the lowest closing bid of the closing price of the common stock of the Company during the ten day period immediately prior to the date a conversion notice is given by the Lender to Regen or (b) \$0.04 per common share as per negotiated as	500,000	14,144,230	Bostonia Partners Timothy Foat, President	Loan

				per negotiated change in original terms and conditions.				
7/28/2025	130,000	131,367	7/28/2026	60% of the lowest price 20 days prior.	0	56,429,124	CFI Capital LLC Ahron Fraiman, Manager	Loan
8/5/2025	100,000	100,904	8/5/2026	60% of the lowest price 20 days prior.	0	43,343,642. 61	Labrys Fund II LP Thomas J. Silverman, General partner	Loan
Total Outstanding Balance:		1,484,702	Total Shares:		13,000,000	306,602,17 4.61		

Any additional material details, including footnotes to the table are below :

Signature:

Name of Principal Executive Officer or Principal Financial Officer: David R Koos

Title: Chairman & CEO

Date: 1/6/2026



Signature: _____

(Digital Signatures should appear as "/s/ [OFFICER NAME]")